SCHEMBL3774572

SCHEMBL3774572

O=C(CN1CCC2(CC1)C(=O)Nc1cccnc12)N1CCN(C2CCC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.42
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
CHRM2 P08172 2/20 0.39
CHRM1 P11229 2/20 0.39
OPRM1 P35372 1/20 0.39
OPRK1 P41145 1/20 0.39
OPRL1 P41146 1/20 0.39
HRH3 Q9Y5N1 3/20 0.38
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
LMNA P02545 2/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CYP2D6 P10635 1/20 0.36
CHRM3 P20309 1/20 0.36
GMNN O75496 1/20 0.36
APEX1 P27695 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3763129 0.85 OPRM1 (0.55) PARP1ALDH1A1KDM4EOPRM1OPRK1
SCHEMBL3770407 0.80 PARP1 (0.41) PARP1ALDH1A1KDM4ECHRM2CHRM1
SCHEMBL23778440 0.79 HRH3 (0.39) ALDH1A1KDM4EHRH3
SCHEMBL23799135 0.78 OPRL1 (0.38) OPRM1OPRK1OPRL1HRH3
SCHEMBL3767750 0.78 OPRM1 (0.44) PARP1ALDH1A1KDM4ECHRM1OPRM1
SCHEMBL20066064 0.77 CHRM4 (0.48) CHRM2CHRM1HRH3CHRM4CHRM5
SCHEMBL3769763 0.73 EGLN1 (0.48) PARP1ALDH1A1KDM4EOPRM1OPRK1
SCHEMBL12402800 0.73 OPRM1 (0.41) OPRM1OPRK1OPRL1HTR1AHTR2A
SCHEMBL13005814 0.73 HRH3 (0.44) ALDH1A1KDM4EHRH3HTTNPSR1
SCHEMBL23799163 0.73 OPRM1 (0.35) OPRM1OPRK1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 PARP1 3744/4885ALDH1A1 1210/4885KDM4E 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.